Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Evolving role of entrectinib in treatment of NTRK-positive tumors.

Evolving role of entrectinib in treatment of NTRK-positive tumors. Future oncology (London, England) Chawla, N., Bui, N. Q., Seetharam, M. 2021

Abstract

Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trkhas proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with intracranial metastasis. Entrectinib is a first-generation Trk inhibitor with impressive activity in early phase trials performed in patients with NTRK fusion positive solid tumors and ROS1 positive non-small-cell lung cancers with subsequent approval for those indications. Entrectinib was also found to be effective in treatment of brain metastasis and generally well tolerated.

View details for DOI 10.2217/fon-2020-0936

View details for PubMedID 33896226